Cancer and neoplasms
The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
Nov
Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725–41. https://doi.org/10.1038/s41571-020-0413-z.
Google Scholar
Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. The Lancet. 2021;398:1002–14. https://doi.org/10.1016/S0140-6736(21)01206-X.
Google Scholar
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49. https://doi.org/10.1146/annurev-pathol-042020-042741.
Google Scholar
Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6:605–18. https://doi.org/10.1016/j.trecan.2020.02.022.
Google Scholar
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603–15. https://doi.org/10.1016/S1470-2045(18)30142-6.
Google Scholar
Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20:1083–97. https://doi.org/10.1016/S1470-2045(19)30274-8.
Google Scholar
Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotech. 2020;65:25–36. https://doi.org/10.1016/j.copbio.2019.11.016.
Google Scholar
Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7:117. https://doi.org/10.1038/s41392-022-00951-x.
Google Scholar
Malvehy J, Samoylenko I, Schadendorf D, Gutzmer R, Grob J, Sacco JJ, et al. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma. J Immunother Cancer. 2021;9:e1621. https://doi.org/10.1136/jitc-2020-001621.
Google Scholar
Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial. NAT MED. 2021;27:1789–96. https://doi.org/10.1038/s41591-021-01510-7.
Google Scholar
Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 2019;47:89–97. https://doi.org/10.1016/j.ebiom.2019.07.066.
Google Scholar
Shoushtari AN, Olszanski AJ, Nyakas M, Hornyak TJ, Wolchok JD, Levitsky V, et al. Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma. Clin Cancer Res. 2022. https://doi.org/10.1158/1078-0432.CCR-22-2046.
Google Scholar
Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, et al. A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemoth Pharm. 2017;79:697–703. https://doi.org/10.1007/s00280-017-3260-6.
Google Scholar
Hwang T, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19:1913–22. https://doi.org/10.1038/mt.2011.132.
Google Scholar
Trager MH, Geskin LJ, Saenger YM. Oncolytic viruses for the treatment of metastatic melanoma. Curr Treat Option On. 2020;21:26. https://doi.org/10.1007/s11864-020-0718-2.
Google Scholar
Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, et al. The role of oncolytic viruses in the treatment of melanoma. Curr Oncol Rep. 2018;20:80. https://doi.org/10.1007/s11912-018-0729-3.
Google Scholar
LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7:35. https://doi.org/10.1186/s40169-018-0214-5.
Google Scholar
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.
Google Scholar
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712–6. https://doi.org/10.1046/j.1445-2197.2003.02748.x.
Google Scholar
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evidence Based Mental Health. 2019;22:153–60. https://doi.org/10.1136/ebmental-2019-300117.
Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–89. https://doi.org/10.1016/j.jclinepi.2021.03.001.
Google Scholar
Neoadjuvant trial of nivolumab in combination with HF10 oncolytic viral therapy in resectable stage IIIB, IIIC, IVM1a Melanoma. (2022). https://clinicaltrials.gov/ct2/show/NCT03259425.
A study of talimogene laherparepvec in stage IIIc and stage IV malignant melanoma. (2015). https://clinicaltrials.gov/ct2/show/NCT00289016.
An extended use study of safety and efficacy of talimogene laherparepvec in melanoma. (2015). https://clinicaltrials.gov/ct2/show/NCT01368276.
Viral therapy in treating patients with metastatic melanoma. (2014). https://clinicaltrials.gov/ct2/show/NCT00651157.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, et al. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria Switzerland and Germany. J Immunother Cancer. 2021;9:e1701. https://doi.org/10.1136/jitc-2020-001701.
Google Scholar
Franke V, Berger DMS, Klop WMC, Hiel B, Wiel BA, Meulen S, et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Int J Cancer. 2019;145:974–8. https://doi.org/10.1002/ijc.32172.
Google Scholar
Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA, et al. Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience. J Am Coll Surg. 2019;228:644–9. https://doi.org/10.1016/j.jamcollsurg.2018.12.027.
Google Scholar
Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, et al. Talimogene laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. J Immunother Cancer. 2018;6:36. https://doi.org/10.1186/s40425-018-0337-7.
Google Scholar
Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. Ann Surg Oncol. 2018;25:3960–5. https://doi.org/10.1245/s10434-018-6803-0.
Google Scholar
Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016;4:12. https://doi.org/10.1186/s40425-016-0116-2.
Google Scholar
Bramante S, Kaufmann JK, Veckman V, Liikanen I, Nettelbeck DM, Hemminki O, et al. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Int J Cancer. 2015;137:1775–83. https://doi.org/10.1002/ijc.29536.
Google Scholar
Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–71. https://doi.org/10.1200/JCO.2009.24.3675.
Google Scholar
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109–19. https://doi.org/10.1016/j.cell.2017.08.027.
Google Scholar
Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2022. https://doi.org/10.1200/JCO.22.00343.
Google Scholar
Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. J Immunother Cancer. 2019;7:145. https://doi.org/10.1186/s40425-019-0623-z.
Google Scholar
Andtbacka RHI, Agarwala SS, Ollila DW, Hallmeyer S, Milhem M, Amatruda T, et al. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck. 2016;38:1752–8. https://doi.org/10.1002/hed.24522.
Google Scholar
Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced unresectable Melanoma. J Clin Oncol. 2018;36:1658–67. https://doi.org/10.1200/JCO.2017.73.7379.
Google Scholar
Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene laherparepvec in combination with Ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:2619–26. https://doi.org/10.1200/JCO.2016.67.1529.
Google Scholar
Schwarze JK, Tijtgat J, Awada G, Cras L, Vasaturo A, Bagnall C, et al. Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. J IMMUNOTHER CANCER. 2022;10:e5141. https://doi.org/10.1136/jitc-2022-005141.
Google Scholar
Stahlie EHA, Franke V, Zuur CL, Klop WMC, van der Hiel B, Van de Wiel BA, et al. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. Cancer Immunol Immunother. 2021;70:2291–300. https://doi.org/10.1007/s00262-020-02839-7.
Google Scholar
García M, Moreno R, Gil-Martin M, Cascallò M, de Olza MO, Cuadra C, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019;30:352–64. https://doi.org/10.1089/hum.2018.107.
Google Scholar
Curti B, Richards J, Faries M, Andtbacka RHI, Grose M, Karpathy R, et al. The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma. ANN ONCOL. 2016;27:i360. https://doi.org/10.1093/annonc/mdw378.06.
Google Scholar
Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. Phase II trial of intravenous administration of reolysin® (reovirus serotype-3-dearing strain) in patients with metastatic melanoma. Mol Ther. 2012;20:1998–2003. https://doi.org/10.1038/mt.2012.146.
Google Scholar
Kaufman HL. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005;115:1903–12. https://doi.org/10.1172/JCI24624.
Google Scholar
Cui C, Wang X, Lian B, Ji Q, Zhou L, Chi Z, et al. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. J Immunother Cancer. 2022;10:e4307. https://doi.org/10.1136/jitc-2021-004307.
Google Scholar
Andtbacka RHI, Curti B, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, et al. Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J Clin Oncol. 2021;39:3829–38. https://doi.org/10.1200/JCO.20.03246.
Google Scholar
Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8. https://doi.org/10.1200/JCO.2014.58.3377.
Google Scholar
Andtbacka RHI, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23:4169–77. https://doi.org/10.1245/s10434-016-5286-0.
Google Scholar
Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Guller U, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther. 2003;14:1497–510. https://doi.org/10.1089/104303403322495016.
Google Scholar
Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, et al. Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol. 2017;19:w179. https://doi.org/10.1093/neuonc/now179.
Google Scholar
Passaro C, Alayo Q, DeLaura I, McNulty J, Grauwet K, Ito H, et al. Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin Cancer Res. 2019;25:290–9. https://doi.org/10.1158/1078-0432.CCR-18-2311.
Google Scholar
Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18:1–15. https://doi.org/10.1007/s40257-016-0238-9.
Google Scholar
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309–37. https://doi.org/10.1016/j.cell.2021.09.020.
Google Scholar
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436–44. https://doi.org/10.1016/S1470-2045(14)70051-8.
Google Scholar
Breitbach CJ, Lichty BD, Bell JC. Oncolytic viruses: therapeutics with an identity crisis. EBioMedicine. 2016;9:31–6. https://doi.org/10.1016/j.ebiom.2016.06.046.
Google Scholar
Park SY, Green AR, Hadi R, Doolittle-Amieva C, Gardner J, Moshiri AS. Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment. J Immunother Cancer. 2022;10:e5257. https://doi.org/10.1136/jitc-2022-005257.
Google Scholar
Audrey-Bayan C, Trager MH, Gartrell-Corrado RD, Rizk EM, Pradhan J, Silverman AM, et al. Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec. Melanoma Res. 2020;30:410–5. https://doi.org/10.1097/CMR.0000000000000661.
Google Scholar
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–62. https://doi.org/10.1038/nrd4663.
Google Scholar
